Could a liquid biopsy detect pancreatic cancer at its earliest stages?
Researchers at City of Hope have developed a new investigational liquid biopsy called PANXEON, designed to detect early-stage pancreatic cancer (stages 1 and 2) and precancerous conditions. This blood-based test combines three biomarkers and artificial intelligence to provide a single risk score.
Why it matters
Pancreatic cancer is notoriously deadly due to late diagnosis, so this innovative test offers the potential for significantly earlier detection, leading to more effective and potentially curative treatment options.
A blood-based miRNA assay has been developed, validated and tested for the detection of early-stage pancreatic ductal adenocarcinoma.
One reason pancreatic cancer remains so deadly is because it’s usually discovered late, after it has spread. Now, a major new study shows that a blood test developed by researchers led by City of Hope, a national leader in pancreatic cancer research, could detect the disease much earlier, when it’s not only more treatable but also potentially curable.
The large, international study found that the new, investigational liquid biopsy, called PANXEON*, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in